Gamal El-Din A Abuo-Rahma
Overview
Explore the profile of Gamal El-Din A Abuo-Rahma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
542
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aziz M, Salem I, Al-Awadh M, Alharbi A, Elsayed Abouzed D, Allam R, et al.
Bioorg Chem
. 2025 Jan;
156:108181.
PMID: 39889555
New pyrazolo[3,4-d]pyrimidine derivatives 7a-h and 8a-h were synthesized and evaluated for their in vitro inhibitory potential against COX-1, COX-2, 5-LOX along with the NO release inhibitory activity to assess their...
2.
Wagih N, Abdel-Rahman I, El-Koussi N, Abuo-Rahma G
RSC Adv
. 2025 Jan;
15(2):966-1010.
PMID: 39807197
Cancer is one of the leading causes of morbidity and mortality worldwide. One of the primary causes of cancer development and progression is epigenetic dysregulation, which is a heritable modification...
3.
Ali D, Aziz H, Brase S, Al Bahir A, Alkhammash A, Abuo-Rahma G, et al.
Molecules
. 2024 Nov;
29(22).
PMID: 39598770
The current study has yielded promising results in the evaluation of a new ciprofloxacin-chalcone hybrid (CP derivative) for its anticancer activity as potential Topoisomerases (Topo) I and II inhibitors. The...
4.
Aziz H, El-Saghier A, Badr M, Elsadek B, Abuo-Rahma G, Shoman M
Sci Rep
. 2024 Oct;
14(1):24101.
PMID: 39406816
A new group of thiazolidine-2,4-dione derivatives of ciprofloxacin having butyryl linker 3a-l was synthesized via an alkylation of thiazolidine-2,4-diones with butyryl ciprofloxacin with yield range 48-77% andfully characterized by various...
5.
Darwish D, El-Sherief H, Abdel-Aziz S, Abuo-Rahma G
Arch Pharm (Weinheim)
. 2024 Mar;
357(6):e2300758.
PMID: 38442316
Over the past decades, cancer has been a challenging domain for medicinal chemists as it is an international health concern. In association, small molecules such as 2-aminothiophenes and their derivatives...
6.
El-Zoghbi M, Bass A, Abuo-Rahma G, Mohamed M, Badr M, Al-Ghulikah H, et al.
Future Med Chem
. 2024 Mar;
16(7):601-622.
PMID: 38436113
The purpose of this work is to create and synthesize a new class of chemicals: 3-cyano-2-substituted pyridine compounds with expected multitarget inhibition of histone deacetylase (HDAC) and tubulin. The target...
7.
Naguib Y, Alhaj-Suliman S, Wafa E, Saha S, Ebeid K, Mohammed H, et al.
Small
. 2023 Aug;
20(41):e2302931.
PMID: 37525558
Combinations of chemotherapeutic agents comprise a clinically feasible approach to combat cancers that possess resistance to treatment. Type II endometrial cancer is typically associated with poor outcomes and the emergence...
8.
Alhaj-Suliman S, Naguib Y, Wafa E, Saha S, Ebeid K, Meng X, et al.
Biomaterials
. 2023 Mar;
296:122093.
PMID: 36965280
Dysfunction of the p53 gene and the presence of the MDR1 gene are associated with many malignant tumors including endometrial cancer and are responsible for cancer therapeutic resistance and poor...
9.
Amin M, Abuo-Rahma G, Shaykoon M, Marzouk A, Abourehab M, Saraya R, et al.
Bioorg Chem
. 2023 Mar;
134:106444.
PMID: 36893547
The present study established thirteen novel 8-hydroxyquinoline/chalcone hybrids3a-mof hopeful anticancer activity. According to NCI screening and MTT assay results, compounds3d-3f, 3i,3k,and3ldisplayed potent growth inhibition on HCT116 and MCF7 cells compared...
10.
Fawzy M, Abu-Baih R, Abuo-Rahma G, Abdel-Rahman I, El-Sheikh A, Nazmy M
Molecules
. 2023 Feb;
28(3).
PMID: 36770806
Novel drugs are desperately needed in order to combat a significant challenge due to chemo-therapeutic resistance and bad prognosis. This research aimed to assess the anticancer activity of a newly...